Novacyt announced unaudited revenue results for the first half of 2018. Unaudited revenues for the first half of 2018 were €7.0 million, with a strong performance in Primerdesign and Lab21 offset by lower than expected sales in NOVAprep®. Group revenues, excluding NOVAprep®, increased 8% (11% at constant exchange rates CER).

The Board expects the Group's full year of 2018 profitability will be higher than previously anticipated excluding the NOVAprep business. Group EBITDA profitability is expected to be higher than previously anticipated in 2018 following the conclusion of the strategic review.